Allergy News and Research

RSS

The term allergy encompasses a wide range of conditions; it is not a disease in itself. In 1906 Clemens von Pirquet was the first to describe allergies as a changed or altered reaction of the immune system in response to exposure to foreign proteins. These days the term allergy – medically termed hypersensitivity, signifies an exaggerated reaction to foreign substances.

Dermatitis management

Although the variety of substances that can cause contact dermatitis is almost limitless, it often can be effectively managed with the proper diagnosis and treatment according to investigators presenting the latest research at the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Seattle.

7 Nov 2008

Efficacy, dosage concerns unresolved on sublingual immunotherapy

Although sublingual immunotherapy (SLIT) is used in Europe and other countries, experts at the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Seattle say questions remain unanswered regarding its effectiveness, appropriate use, dosage, and safety of administration.

7 Nov 2008

BioCis Pharma starts phase IIa clinical testing of ProtoCure in atopic dermatitis

BioCis Pharma Ltd a privately-held drug development company with its headquarters in Turku, Finland, announced that it has begun Phase IIa clinical testing of ProtoCure(TM) emulsion cream, the company's novel topical drug for dermatology.

7 Nov 2008

A probiotic bacterium reduces hospital infections

A probiotic bacterium, Lactobacillus plantarum 299, has been used to out-compete the dangerous bacteria that cause respiratory illness in ventilated patients.

6 Nov 2008

Contaminants in human milk

An overview of studies on environmental pollutants in human milk has found that not breastfeeding an infant typically poses more of a threat than does exposure to any of the chemical agents measured in human milk, as reported in the 11th Annual Children’s Health Issue of Environmental Health Perspectives (EHP).

6 Nov 2008

Flu shot still best protection against flu

The failure of the flu vaccine to protect many Americans against the virus last year shouldn't prevent you from getting your annual flu shot this year.

6 Nov 2008

YM Biosciences reports on early trials of nimotuzumab in brain metastases and high-grade glioma

YM BioSciences Inc. has announced data from two clinical trials of nimotuzumab, its humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR). Preliminary results from the two trials which are evaluating nimotuzumab in combination with radiation therapy for the treatment of brain metastases and high-grade gliomas, conducted by YM's licensor, were presented at the 2008 EORTC-NCI-AACR annual meeting recently held in Geneva, Switzerland.

3 Nov 2008

MedImmune starts phase 1/2a clinical trial for respiratory syncytial virus vaccine

MedImmune today announced that it has initiated a Phase 1/2a clinical trial of a live, attenuated intranasal vaccine in healthy children one month to 12 months of age to help prevent severe respiratory syncytial virus (RSV) infections. RSV is the most common respiratory infection in infants and can cause disease in otherwise healthy infants and children.

3 Nov 2008

Persistent bacterial infection exploits killing machinery of immune cells

A new study reveals an important and newly discovered pathway used by disease-causing bacteria to evade the host immune system and survive and grow within the very cells meant to destroy them. This discovery may lead to new treatments and vaccines for tuberculosis (TB) and certain other chronic bacterial and parasitic infections.

3 Nov 2008

Discovery of new pathway used by disease-causing bacteria to evade host immune system and survive

2 Nov 2008

Bacteria can directly cause human blood and plasma to clot

Bacteria can directly cause human blood and plasma to clot - a process that was previously thought to have been lost during the course of vertebrate evolution, according to new research at the University of Chicago, National Institute of Allergy and Infectious Diseases, and Institut Pasteur in Paris. Their findings will be published online Nov. 2 in Nature Chemical Biology.

2 Nov 2008

Drinking milk to ease milk allergy?

Giving children with milk allergies increasingly higher doses of milk over time may ease, and even help them completely overcome, their allergic reactions, according to the results of a study led by the Johns Hopkins Children's Center and conducted jointly with Duke University.

29 Oct 2008

Rice can trigger a severe allergic reaction in babies

According to new research by Australian doctors, contrary to the current view of it as a hypo-allergenic foodstuff, rice can trigger a severe allergic reaction in babies.

29 Oct 2008

The sooner the better when it comes to HIV/AIDS treatment

New research into HIV/AIDS therapy has found that starting treatment with drugs for the AIDS virus may be better sooner than later as victims are more than 70% less likely to die when they started taking cocktails of HIV drugs earlier than currently recommended.

27 Oct 2008

3 million U.S. children have food or digestive allergies

The number of young people who had a food or digestive allergy increased 18 percent between 1997 and 2007, according to a new report by the Centers for Disease Control and Prevention. In 2007, approximately 3 million U.S. children and teenagers under age 18 -- or nearly 4 percent of that age group -- were reported to have a food or digestive allergy in the previous 12 months, compared to just over 2.3 million (3.3 percent) in 1997.

22 Oct 2008

Aires Pharmaceuticals signs license agreement with NIH

Aires Pharmaceuticals Inc. today announced the signing of an exclusive license agreement with the U.S. National Institutes of Health for the patented use of a nitric oxide prodrug to treat cardiopulmonary conditions.

22 Oct 2008

Trius Therapeutics awarded $28 million to develop novel drugs targeting bacterial DNA Gyrase and Topoisomerase IV

Trius Therapeutics, Inc., today announced the award of a $28 million contract from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, for the development of novel antibiotics directed against multiple Gram-negative bacterial pathogens.

22 Oct 2008